PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CA2611938) MODIFIED RELEASE TICLOPIDINE COMPOSITIONS

Office : Canada
Application Number: 2611938 Application Date: 09.06.2006
Publication Number: 2611938 Publication Date: 25.01.2007
Publication Kind : A1
Prior PCT appl.: Application Number:US2006022597 ; Publication Number: Click to see the data
IPC:
A61K 9/26
A61K 9/14
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
22
Sustained or differential release type
26
Discrete particles in supporting matrix
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
CPC:
A61K 9/5084
A61K 9/1676
A61K 9/5026
A61K 9/5078
Applicants: ELAN CORPORATION, PLC
Inventors: LIVERSIDGE, GARY
JENKINS, SCOTT
STARK, PAUL
FANNING, NIALL
REKHI, GURVINDER
DEVANE, JOHN
CHRISTENSEN, BRUCE J.
Priority Data: 11/372,857 10.03.2006 US
60/689,931 13.06.2005 US
Title: (EN) MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
(FR) COMPOSITIONS DE TICLOPIDINE A DIFFUSION MODIFIEE
Abstract:
(EN) The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.


Also published as:
EP1901718JP2009516636US20090297597WO/2007/011473